At the 2022 Roth Conference in California, InMed’s CEO, Eric A. Adams, sat down with Roth Capital Analyst Scott R. Henry in a fireside chat.
During their discussion, Eric talks about InMed’s upcoming launch of rare cannabinoids CBDV and THCV as wholesale raw ingredients for the health and wellness sector. They also discuss the growing interest for minor cannabinoids and how the company is well positioned with short and long term investment value that includes revenues from wholesale cannabinoid ingredients and its longer term pharmaceutical development programs. Eric also gives an update on the company’s INM-755, a Phase 2 clinical program using a cannabinol CBN cream for the treatment of epidermolysis bullosa, and INM-088, a preclinical program using a cannabinol (CBN) eye drop for the treatment of glaucoma.
Register free to watch this fireside chat: https://wsw.com/webcast/roth43/inm2/1748056
